FDA approves Teva's generic EpiPenTeva shares were up after U.S. regulators approved its generic version of Mylan's EpiPen auto-injector for the emergency treatment of severe allergic shock, the Financial Times said on Thursday (APMHE 59348).
Jury awards $289 million damages in Monsanto cancer trialBayer's shares plunged after its recently-acquired subsidiary Monsanto was hit with $289 million in damages after a jury in San Francisco ruled that a former school ground keeper's terminal cancer had been caused by a popular chemical weed killer produced by the U.S. seeds and chemical group, the FT said on Monday.
Bayer saves Essure lawsuit in AustraliaBayer is facing a lawsuit in Australia over its Essure contraceptive, the Guardian said on Monday.
Positive results for ViiV Healthcare's two drug monthly injection for HIVViiV Healthcare has reported data from a Phase III study that could support cutting HIV treatment from a daily dose of three drugs to a monthly injection of two, the FT said on Wednesday (APMHE 59317).
Hikma raises forecasts after strong start to 2018UK-based Hikma Pharmaceuticals raised its 2018 forecasts after a positive first half of the year, it was reported in The Times and The Financial Times on Thursday (APMHE 59318).
Brexit cannot be allowed to disrupt medicines' supplyThursday's FT carried an opinion piece from Layla McCay, secretary of the Brexit Health Alliance, who said that Brexit must not be allowed to disrupt access to medicines in the UK and Europe.
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to our last stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.